Log in

NASDAQ:HZNPHorizon Therapeutics Stock Price, Forecast & News

$49.56
+1.63 (+3.40 %)
(As of 05/25/2020 04:00 PM ET)
Add
Compare
Today's Range
$47.73
Now: $49.56
$49.81
50-Day Range
$30.20
MA: $36.85
$47.93
52-Week Range
$22.69
Now: $49.56
$49.81
Volume2.47 million shs
Average Volume2.02 million shs
Market Capitalization$9.45 billion
P/E Ratio17.51
Dividend YieldN/A
Beta1.08
Horizon Therapeutics Public Limited Company, a biopharmaceutical company, focuses on researching, developing, and commercializing medicines that address unmet treatment needs for rare and rheumatic diseases in the United States and internationally. Its orphan and rheumatology marketed medicines include KRYSTEXXA, a medicine for the treatment of uncontrolled gout; RAVICTI for use as a nitrogen-binding agent for chronic management of adult and pediatric patients; PROCYSBI for nephropathic cystinosis, a rare and life-threatening metabolic disorder; ACTIMMUNE for chronic granulomatous disease; RAYOS for the treatment of multiple conditions, rheumatoid arthritis; BUPHENYL tablets for oral administration and BUPHENYL powder for oral, nasogastric, or gastrostomy tube administration; and QUINSAIR, a formulation of the antibiotic drug levofloxacin for the management of chronic pulmonary infections due to Pseudomonas aeruginosa in adult patients with cystic fibrosis. The company's primary care marketed medicines comprise PENNSAID 2% that is indicated for the treatment of pain of osteoarthritis of the knees; DUEXIS for the relief of signs and symptoms of RA and OA, and to decrease the risk of developing upper-GI ulcers; VIMOVO for the relief of signs and symptoms of OA, RA, and AS and to decrease the risk of developing gastric ulcers in patients at risk of developing NSAID-associated gastric ulcers; and MIGERGOT, a therapy to abort or prevent vascular headaches, such as migraines and migraine variants. It has collaboration agreements with Alliance for Lupus Research, Syneos Health, Inc., and HemoShear Therapeutics, LLC. The company was formerly known as Horizon Pharma Public Limited Company and changed its name to Horizon Therapeutics Public Limited Company in May 2019. Horizon Therapeutics Public Limited Company was founded in 2005 and is headquartered in Dublin, Ireland.
Read More
Horizon Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 2.5Community Rank: 3.3Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 2.5 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.85 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
Current SymbolNASDAQ:HZNP
CUSIP44047T10
Phone011-353-1772-2100

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$1.30 billion
Cash Flow$3.47 per share
Book Value$11.67 per share

Profitability

Net Income$573.02 million

Miscellaneous

Employees1,200
Market Cap$9.45 billion
Next Earnings Date8/5/2020 (Estimated)
OptionableOptionable

Receive HZNP News and Ratings via Email

Sign-up to receive the latest news and ratings for HZNP and its competitors with MarketBeat's FREE daily newsletter.

Horizon Therapeutics (NASDAQ:HZNP) Frequently Asked Questions

How has Horizon Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Horizon Therapeutics' stock was trading at $30.51 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, HZNP shares have increased by 62.4% and is now trading at $49.56. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Horizon Therapeutics?

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Horizon Therapeutics in the last year. There are currently 1 hold rating and 11 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Horizon Therapeutics.

When is Horizon Therapeutics' next earnings date?

Horizon Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020. View our earnings forecast for Horizon Therapeutics.

How were Horizon Therapeutics' earnings last quarter?

Horizon Therapeutics PLC (NASDAQ:HZNP) announced its quarterly earnings results on Wednesday, May, 6th. The biopharmaceutical company reported $0.40 EPS for the quarter, topping analysts' consensus estimates of $0.21 by $0.19. The biopharmaceutical company had revenue of $355.90 million for the quarter, compared to analyst estimates of $287.88 million. Horizon Therapeutics had a net margin of 43.06% and a return on equity of 22.52%. The business's revenue was up 26.9% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.30 EPS. View Horizon Therapeutics' earnings history.

What guidance has Horizon Therapeutics issued on next quarter's earnings?

Horizon Therapeutics updated its FY 2020 Pre-Market earnings guidance on Wednesday, May, 6th. The company provided EPS guidance of for the period. The company issued revenue guidance of $1.4-1.45 billion, compared to the consensus revenue estimate of $1.35 billion.

What price target have analysts set for HZNP?

12 Wall Street analysts have issued 1-year price targets for Horizon Therapeutics' stock. Their forecasts range from $35.00 to $61.00. On average, they expect Horizon Therapeutics' stock price to reach $44.42 in the next year. This suggests that the stock has a possible downside of 10.4%. View analysts' price targets for Horizon Therapeutics.

Has Horizon Therapeutics been receiving favorable news coverage?

Media coverage about HZNP stock has trended very positive on Monday, according to InfoTrie Sentiment Analysis. The research group rates the sentiment of press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Horizon Therapeutics earned a coverage optimism score of 4.0 on InfoTrie's scale. They also assigned media stories about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the company's share price in the near future. View the latest news aboutHorizon Therapeutics.

Who are some of Horizon Therapeutics' key competitors?

What other stocks do shareholders of Horizon Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Horizon Therapeutics investors own include Alibaba Group (BABA), Opko Health (OPK), NVIDIA (NVDA), Netflix (NFLX), Gilead Sciences (GILD), Advanced Micro Devices (AMD), Vertex Pharmaceuticals (VRTX), AbbVie (ABBV), Bank of America (BAC) and Paypal (PYPL).

Who are Horizon Therapeutics' key executives?

Horizon Therapeutics' management team includes the following people:
  • Mr. Timothy P. Walbert, Chairman, Pres & CEO (Age 52)
  • Mr. Paul W. Hoelscher, Exec. VP & CFO (Age 54)
  • Dr. Shao-Lee Lin M.D., Ph.D., Exec. VP, Head of R&D and Chief Scientific Officer (Age 52)
  • Mr. Barry J. Moze, Exec. VP & Chief Admin. Officer (Age 65)
  • Mr. Robert F. Carey, Exec. VP & Chief Bus. Officer (Age 60)

What is Horizon Therapeutics' stock symbol?

Horizon Therapeutics trades on the NASDAQ under the ticker symbol "HZNP."

Who are Horizon Therapeutics' major shareholders?

Horizon Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (5.40%), William Blair Investment Management LLC (4.38%), Janus Henderson Group PLC (3.50%), JPMorgan Chase & Co. (2.17%), Invesco Ltd. (1.53%) and State Street Corp (1.40%). Company insiders that own Horizon Therapeutics stock include Barry Moze, Brian K Beeler, Geoffrey M Curtis, Irina Konstantinovsky, James Samuel Shannon, Jeff Kent, Jeffrey W Sherman, Miles W Mchugh, Paul W Hoelscher, Timothy P Walbert and Vikram Karnani. View institutional ownership trends for Horizon Therapeutics.

Which institutional investors are selling Horizon Therapeutics stock?

HZNP stock was sold by a variety of institutional investors in the last quarter, including Nuveen Asset Management LLC, APG Asset Management N.V., APG Asset Management N.V., Invesco Ltd., William Blair Investment Management LLC, Balyasny Asset Management LLC, Two Sigma Advisers LP, and Russell Investments Group Ltd.. Company insiders that have sold Horizon Therapeutics company stock in the last year include Barry Moze, Brian K Beeler, Geoffrey M Curtis, Irina Konstantinovsky, James Samuel Shannon, Jeff Kent, Jeffrey W Sherman, Miles W Mchugh, Paul W Hoelscher, Timothy P Walbert, and Vikram Karnani. View insider buying and selling activity for Horizon Therapeutics.

Which institutional investors are buying Horizon Therapeutics stock?

HZNP stock was purchased by a variety of institutional investors in the last quarter, including Viking Global Investors LP, Janus Henderson Group PLC, Orbimed Advisors LLC, Redwood Investments LLC, Scout Investments Inc., Samlyn Capital LLC, Carillon Tower Advisers Inc., and JPMorgan Chase & Co.. View insider buying and selling activity for Horizon Therapeutics.

How do I buy shares of Horizon Therapeutics?

Shares of HZNP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Horizon Therapeutics' stock price today?

One share of HZNP stock can currently be purchased for approximately $49.56.

How big of a company is Horizon Therapeutics?

Horizon Therapeutics has a market capitalization of $9.45 billion and generates $1.30 billion in revenue each year. The biopharmaceutical company earns $573.02 million in net income (profit) each year or $1.94 on an earnings per share basis. Horizon Therapeutics employs 1,200 workers across the globe.

What is Horizon Therapeutics' official website?

The official website for Horizon Therapeutics is www.horizontherapeutics.com.

How can I contact Horizon Therapeutics?

Horizon Therapeutics' mailing address is 1 BURLINGTON ROAD CONNAUGHT HOUSE 1ST FLOOR, Dublin L2, D04 C5Y6. The biopharmaceutical company can be reached via phone at 011-353-1772-2100 or via email at [email protected]

This page was last updated on 5/25/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.